Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study
- PMID: 38246190
- DOI: 10.1016/S1473-3099(23)00688-6
Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study
Abstract
Background: Between 2018 and 2022, Nigeria experienced continuous transmission of circulating vaccine-derived type 2 poliovirus (cVDPV2), with 526 cases of cVDPV2 poliomyelitis detected in total and approximately 180 million doses of monovalent type 2 oral poliovirus vaccine (mOPV2) and 450 million doses of novel type 2 oral poliovirus vaccine (nOPV2) delivered in outbreak response campaigns. Inactivated poliovirus vaccine (IPV) was introduced into routine immunisation in 2015, with a second dose added in 2021. We aimed to estimate the effectiveness of nOPV2 against cVDPV2 paralysis and compare nOPV2 effectiveness with that of mOPV2 and IPV.
Methods: In this retrospective case-control study, we used acute flaccid paralysis (AFP) surveillance data in Nigeria from Jan 1, 2017, to Dec 31, 2022, using age-matched, onset-matched, and location-matched cVDPV2-negative AFP cases as test-negative controls. We also did a parallel prospective study from March, 2021, using age-matched community controls from the same settlement as the cases. We included children born after May, 2016, younger than 60 months, for whom polio immunisation history (doses of OPV from campaigns and IPV) was reported. We estimated the per-dose effectiveness of nOPV2 against cVDPV2 paralysis using conditional logistic regression and compared nOPV2 effectiveness with that of mOPV2 and IPV.
Findings: In the retrospective case-control study, we identified 509 cVDPV2 poliomyelitis cases in Nigeria with case verification and paralysis onset between Jan 1, 2017, and Dec 31, 2022. Of these, 82 children were excluded for not meeting inclusion criteria, and 363 (85%) of 427 eligible cases were matched to 1303 test-negative controls. Cases reported fewer OPV and IPV doses than test-negative controls (mean number of OPV doses 5·9 [SD 4·2] in cases vs 6·7 [4·3] in controls; one or more IPV doses reported in 95 [26%] of 363 cases vs 513 [39%] of 1303 controls). We found low per-dose effectiveness of nOPV2 (12%, 95% CI -2 to 25) and mOPV2 (17%, 3 to 29), but no significant difference between the two vaccines (p=0·67). The estimated effectiveness of one IPV dose was 43% (23 to 58). In the prospective study, 181 (46%) of 392 eligible cases were matched to 1557 community controls. Using community controls, we found a high effectiveness of IPV (89%, 95% CI 83 to 93, for one dose), a low per-dose effectiveness of nOPV2 (-23%, -45 to -5) and mOPV2 (1%, -23 to 20), and no significant difference between the per-dose effectiveness of nOPV2 and mOPV2 (p=0·12).
Interpretation: We found no significant difference in estimated effectiveness of the two oral vaccines, supporting the recommendation that the more genetically stable nOPV2 should be preferred in cVDPV2 outbreak response. Our findings highlight the role of IPV and the necessity of strengthening routine immunisation, the primary route through which IPV is delivered.
Funding: Bill & Melinda Gates Foundation and UK Medical Research Council.
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Similar articles
-
Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.Lancet Infect Dis. 2022 Feb;22(2):284-294. doi: 10.1016/S1473-3099(21)00453-9. Epub 2021 Oct 11. Lancet Infect Dis. 2022. PMID: 34648733 Free PMC article.
-
Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A35-A47. doi: 10.1016/j.vaccine.2023.02.042. Epub 2023 Mar 11. Vaccine. 2023. PMID: 36907733 Free PMC article.
-
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.Lancet Microbe. 2022 Dec;3(12):e912-e921. doi: 10.1016/S2666-5247(22)00254-3. Epub 2022 Nov 1. Lancet Microbe. 2022. PMID: 36332645 Free PMC article.
-
Deployment of novel oral polio vaccine type 2 under emergency use listing in Nigeria: the rollout experience.Pan Afr Med J. 2023 Jul 13;45(Suppl 2):3. doi: 10.11604/pamj.supp.2023.45.2.38033. eCollection 2023. Pan Afr Med J. 2023. PMID: 38370105 Free PMC article. Review.
-
Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A113-A121. doi: 10.1016/j.vaccine.2022.03.027. Epub 2022 Mar 29. Vaccine. 2023. PMID: 35365341 Free PMC article. Review.
Cited by
-
Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.Pathogens. 2024 May 22;13(6):435. doi: 10.3390/pathogens13060435. Pathogens. 2024. PMID: 38921733 Free PMC article. Review.
-
Novel Oral Polio Vaccine Type 2 Use for Polio Outbreak Response: A Global Effort for a Global Health Emergency.Pathogens. 2024 Mar 23;13(4):273. doi: 10.3390/pathogens13040273. Pathogens. 2024. PMID: 38668228 Free PMC article. Review.
-
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224. Pathogens. 2024. PMID: 38535567 Free PMC article. Review.
-
Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021-2022, a retrospective descriptive analysis.BMC Infect Dis. 2024 Mar 15;24(1):321. doi: 10.1186/s12879-024-09215-1. BMC Infect Dis. 2024. PMID: 38491425 Free PMC article.
-
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.Lancet. 2024 Mar 23;403(10432):1164-1175. doi: 10.1016/S0140-6736(23)02844-1. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402887 Free PMC article. Clinical Trial.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials